Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The effect of germline mutations on therapeutic r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Wang, Cong, Chen, Fang, Liu, Yichen, Xu, Qingqing, Guo, Liang, Zhang, Xiaoqing, Ruan, Yunfeng, Shi, Ye, Shen, Lu, Li, Mo, Du, Huihui, Sun, Xiaofang, Ma, Jingsong, He, Lin, Qin, Shengying
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5904969/
https://ncbi.nlm.nih.gov/pubmed/29695969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00360
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky